The following is an excerpt.
Americans seeking stem cell replacement therapy hope the process can heal them of myriad diseases, and a 2011 report by the Baker Institute estimated the industry could bring in $16 billion in revenue by 2020.
But the Food and Drug Administration has expressed concerns. The agency sued to stop treatments at a Regenerative Sciences clinic in Colorado and closed the labof another company, Celltex Therapeutics, in Texas.
While patients in dire situations are willing to try the therapy (and pay the hefty costs), there’s concern the research doesn’t support broad practice just yet.
Read the full article here: FDA Challenges Stem Cell Companies As Patients Run Out Of Time
- Wild West of stem cells?, Genetic Literacy Project
- Stem cell showdown: Small business versus the FDA, Bloomberg BusinessWeek
- Controversial stem-cell company moves treatment out of the United States, Nature News